JP2020532956A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532956A5 JP2020532956A5 JP2020507093A JP2020507093A JP2020532956A5 JP 2020532956 A5 JP2020532956 A5 JP 2020532956A5 JP 2020507093 A JP2020507093 A JP 2020507093A JP 2020507093 A JP2020507093 A JP 2020507093A JP 2020532956 A5 JP2020532956 A5 JP 2020532956A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hla
- ebv
- positive
- epstein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0101800 | 2017-08-10 | ||
| KR20170101800 | 2017-08-10 | ||
| PCT/KR2018/009224 WO2019031938A2 (ko) | 2017-08-10 | 2018-08-10 | 암 치료를 위한 t 세포의 활성화 방법 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532956A JP2020532956A (ja) | 2020-11-19 |
| JP2020532956A5 true JP2020532956A5 (https=) | 2021-09-09 |
| JP7364237B2 JP7364237B2 (ja) | 2023-10-18 |
Family
ID=65271692
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507103A Active JP7693189B2 (ja) | 2017-08-10 | 2018-08-10 | 癌治療のためのｔ細胞の活性化方法 |
| JP2020507093A Active JP7364237B2 (ja) | 2017-08-10 | 2018-08-10 | 癌治療のためのｔ細胞の活性化方法 |
| JP2023093867A Withdrawn JP2023113855A (ja) | 2017-08-10 | 2023-06-07 | 癌治療のためのｔ細胞の活性化方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507103A Active JP7693189B2 (ja) | 2017-08-10 | 2018-08-10 | 癌治療のためのｔ細胞の活性化方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093867A Withdrawn JP2023113855A (ja) | 2017-08-10 | 2023-06-07 | 癌治療のためのｔ細胞の活性化方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11918634B2 (https=) |
| EP (2) | EP3666887A4 (https=) |
| JP (3) | JP7693189B2 (https=) |
| KR (5) | KR102148866B1 (https=) |
| CN (2) | CN110997903B (https=) |
| BR (1) | BR112020002816A2 (https=) |
| WO (2) | WO2019031939A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3922642A4 (en) * | 2019-02-08 | 2023-03-29 | Good T Cells, Inc. | METHOD OF ACTIVATING T LYMPHOCYTES FOR THE TREATMENT OF CANCER |
| EP3927361A4 (en) * | 2019-02-21 | 2022-11-30 | Ramot at Tel-Aviv University Ltd. | TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES |
| KR102182555B1 (ko) * | 2019-03-14 | 2020-11-24 | 한국과학기술연구원 | T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼 |
| KR102335916B1 (ko) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| US20220364079A1 (en) * | 2019-09-23 | 2022-11-17 | Dana-Farber Cancer Institute, Inc. | Methods of high-throughput identification of t cell epitopes by capturing cytokines on the surface of antigen-presenting cells |
| KR20210102089A (ko) | 2020-02-11 | 2021-08-19 | 주식회사 리스큐어바이오사이언시스 | 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물 |
| CN116018158A (zh) * | 2020-04-30 | 2023-04-25 | 转化基因组学研究所 | 新抗原知情的肿瘤浸润性淋巴细胞癌免疫疗法 |
| GB202010095D0 (en) * | 2020-07-01 | 2020-08-12 | Tcer Ab | Immunotherapy |
| KR20220118225A (ko) | 2021-02-18 | 2022-08-25 | 주식회사 리스큐어바이오사이언시스 | 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물 |
| KR20220131170A (ko) | 2021-03-19 | 2022-09-27 | 주식회사 리스큐어바이오사이언시스 | 미성숙 수지상 세포의 성숙화 유도를 이용한 암의 예방 또는 치료용 조성물 |
| CN114230655B (zh) * | 2021-03-24 | 2025-02-25 | 深圳市新靶向生物科技有限公司 | 一种与食道癌驱动基因突变相关的抗原肽组合及其应用 |
| US20250313801A1 (en) * | 2022-05-26 | 2025-10-09 | Suzhou Ersheng Biomedical Co., Ltd. | Specific t cell for preventing or treating cancer, and preparation method thereof |
| WO2024151124A1 (ko) * | 2023-01-12 | 2024-07-18 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| WO2025240737A1 (en) * | 2024-05-16 | 2025-11-20 | Rutgers, The State University Of New Jersey | Methods of producing memory t cells in vitro and their use in immunotherapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| JP2005530493A (ja) | 2002-04-22 | 2005-10-13 | レコファーマ アーベー | ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法 |
| GB0214528D0 (en) | 2002-06-24 | 2002-08-07 | Univ Aberdeen | Materials and methods for induction of immune tolerance |
| US7619058B2 (en) * | 2004-01-20 | 2009-11-17 | Aichi Prefecture | Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| JP4824389B2 (ja) * | 2005-10-28 | 2011-11-30 | 株式会社医学生物学研究所 | エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| TWI596109B (zh) * | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| CA2730742C (en) | 2008-07-16 | 2017-05-23 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| CN101643497A (zh) * | 2009-09-15 | 2010-02-10 | 南京医科大学 | Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途 |
| GB0917090D0 (en) | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| JP6130307B2 (ja) * | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| CN104769104A (zh) | 2011-12-12 | 2015-07-08 | 细胞药物有限公司 | 扩大t细胞的方法 |
| GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
| CN107002038B (zh) | 2014-09-17 | 2021-10-15 | 约翰·霍普金斯大学 | 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法 |
| CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| TW202523682A (zh) * | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| CN107709351A (zh) | 2015-06-17 | 2018-02-16 | 株式会社医学生物学研究所 | 细胞毒性t细胞表位肽及其用途 |
| AU2016339924B2 (en) * | 2015-10-12 | 2020-01-02 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| CA3003251A1 (en) * | 2015-10-12 | 2017-04-20 | Nantomics, Llc | Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors |
| RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| EP3463398A4 (en) * | 2016-05-25 | 2020-03-11 | The Council of the Queensland Institute of Medical Research | IMMUNE CONTROL POINT INHIBITORS AND CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF CANCER |
| PT3488443T (pt) * | 2016-07-20 | 2021-09-24 | BioNTech SE | Seleção de neoepítopos como alvos específicos da doença para terapia com eficácia melhorada |
-
2018
- 2018-08-10 CN CN201880052032.2A patent/CN110997903B/zh active Active
- 2018-08-10 US US16/638,055 patent/US11918634B2/en active Active
- 2018-08-10 WO PCT/KR2018/009225 patent/WO2019031939A2/ko not_active Ceased
- 2018-08-10 BR BR112020002816-9A patent/BR112020002816A2/pt not_active Application Discontinuation
- 2018-08-10 WO PCT/KR2018/009224 patent/WO2019031938A2/ko not_active Ceased
- 2018-08-10 CN CN201880052033.7A patent/CN111433355B/zh active Active
- 2018-08-10 EP EP18843560.6A patent/EP3666887A4/en not_active Withdrawn
- 2018-08-10 EP EP18844804.7A patent/EP3666888A4/en not_active Withdrawn
- 2018-08-10 KR KR1020180093946A patent/KR102148866B1/ko active Active
- 2018-08-10 JP JP2020507103A patent/JP7693189B2/ja active Active
- 2018-08-10 JP JP2020507093A patent/JP7364237B2/ja active Active
- 2018-08-10 US US16/637,927 patent/US11969463B2/en active Active
- 2018-08-10 KR KR1020180093897A patent/KR102190890B1/ko active Active
-
2020
- 2020-08-21 KR KR1020200105269A patent/KR20200102402A/ko not_active Withdrawn
- 2020-12-08 KR KR1020200170517A patent/KR20200141424A/ko not_active Ceased
-
2022
- 2022-09-08 KR KR1020220114288A patent/KR20220136957A/ko not_active Ceased
-
2023
- 2023-06-07 JP JP2023093867A patent/JP2023113855A/ja not_active Withdrawn
-
2024
- 2024-01-25 US US18/423,189 patent/US20240156927A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532956A5 (https=) | ||
| JP2020532957A5 (https=) | ||
| Mitchell et al. | Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells | |
| JP7034955B2 (ja) | 免疫療法向けのｔ細胞組成物 | |
| Goodier et al. | CMV and natural killer cells: shaping the response to vaccination | |
| JP2019519246A5 (https=) | ||
| Méndez-Samperio | Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease | |
| JP6333730B2 (ja) | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 | |
| JP7078937B2 (ja) | 免疫細胞を操作するための抗原提示足場 | |
| Cayeux et al. | Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation | |
| JP7364237B2 (ja) | 癌治療のためのｔ細胞の活性化方法 | |
| Callan | The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein-Barr virus | |
| JP2020022505A5 (https=) | ||
| Berger et al. | Adoptive transfer of virus-specific and tumor-specific T cell immunity | |
| Stewart et al. | The interleukin-10 homolog encoded by Eepstein-Barr virus enhances the reactivation of virus-specific cytotoxic T cell and HLA-unrestricted killer cell responses | |
| JP2019507608A5 (https=) | ||
| Huss et al. | TGF‐β signaling via Smad4 drives IL‐10 production in effector Th1 cells and reduces T‐cell trafficking in EAE | |
| JP6697076B2 (ja) | ウイルス抗原特異的ｔ細胞の濃縮および拡大方法 | |
| Akuffo et al. | Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells | |
| Rizza et al. | Cytokines as natural adjuvants for vaccines: where are we now? | |
| JP2022519378A (ja) | がん治療のためのｔ細胞の活性化方法 | |
| JP2019536429A5 (https=) | ||
| Sad et al. | Maintenance and attrition of T-cell memory | |
| Pennisi et al. | Agent based modeling of lung metastasis-immune system competition | |
| Turksma et al. | Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells |